Altria Q3 2026: a beat, a raised outlook, and the volume question

Altria (MO) reported third-quarter adjusted EPS of $1.52 before the open on Oct 29, a penny above the $1.51 consensus and up 4.8% from a year ago. Revenue beat by more, and management raised the bottom of its 2026 guidance. After a two-cent miss in Q2, this quarter puts Altria back on the beat side.

$1.52Adjusted EPS vs $1.51 expected

$5.44BRevenue net of excise taxes vs $5.31B expected

$5.66–5.742026 EPS guidance, raised from $5.61–5.72

~6.1%Dividend yield at the Oct 28 close of $72.99

Bottom line

Clean beat on both lines. Adjusted EPS beat by $0.01; revenue net of excise taxes beat by about $130 million (+2.5%) and grew 3.6% year over year.
Guidance up. The 2026 range moved to $5.66–$5.74 (4.5%–6.0% growth over 2025's $5.42). The midpoint rose from about $5.67 to $5.70.
Pricing still beats volume. Domestic cigarette shipments fell 2.9% (about 4% adjusted for inventory), yet smokeable operating income rose 3.9%.
More cash back to holders. A $1 billion expansion of the buyback, now running through 2027, on top of a dividend raised 4.7% in August.
The soft spot is oral tobacco. on! pouches grew 13.3%, but Copenhagen and Skoal fell double digits and on! lost share of the pouch category.

The scorecard

Measure	Q3 2026	Expected / prior	Change
Adjusted diluted EPS	$1.52	$1.51 consensus	+4.8% y/y (from $1.45)
Reported diluted EPS	$1.51	—	+7.1% y/y
Revenue net of excise taxes	$5.44B	$5.31B consensus	+3.6% y/y
Net revenue (incl. excise)	$6.13B	—	+1.0% y/y
2026 adjusted EPS guidance	$5.66–$5.74	$5.61–$5.72	Raised

For context, Q2 2026 was a miss: $1.48 against a $1.50 consensus. MarketBeat counted beats in 6 of Altria's 8 quarters before this report.

How Altria grows while smoking shrinks

The core of the story has not changed in a decade: fewer cigarettes, higher prices, wider margins. This quarter fit the pattern.

Inside the cigarette numbers there was a notable mix shift. Marlboro shipments fell 6.4% to 13.32 billion sticks, and Marlboro's retail share slipped a full point to 39.5%. Altria's own discount-brand shipments jumped 40.5% to 1.70 billion. Even so, smokeable revenue net of excise taxes rose 3.7% to $4.76 billion, operating income rose 3.9% to $3.07 billion, and the margin edged up to 64.5%.

Black & Mild cigars were steady, with shipments up 0.9% to 456 million.

Oral tobacco: on! grows, the old brands fade

Measure	Q3 2026	Change y/y
Total oral shipments	170.6M cans	−4.3% (about −5% adjusted)
on! shipments	47.8M cans	+13.3%
Copenhagen shipments	—	−10.1%
Skoal shipments	—	−12.6%
on! share of nicotine-pouch category	13.5%	−1.3 pts
Oral operating income	$443M	−3.7% (margin 66.4%, −2.8 pts)

on! is growing, but the pouch category is growing faster, so on! is losing share to competitors. Altria expanded on! PLUS 12 mg nationally and added flavors this quarter. Meanwhile, Altria still does not expect its NJOY ACE e-vapor device back on the U.S. market in 2026, so e-vapor adds little to results for now.

Why it matters. Moist snuff (Copenhagen, Skoal) is a high-margin business in decline. Whether on! can grow fast enough to replace that profit is the main open question in Altria's smoke-free plan.

Cash returns: the income case

Dividend: raised 4.7% in August to an annualized $4.44 a share, Altria's 61st increase in 57 years. That is about a 6.1% yield at the Oct 28 close of $72.99.
Buybacks: 5.9 million shares for $400 million in Q3 (average $68.52), and $735 million so far in 2026. The board added $1 billion to the program, which now runs through Dec. 31, 2027.
Balance sheet: total debt fell to $24.06 billion from $25.71 billion at the end of 2025; cash fell to $2.70 billion from $4.47 billion.

At $72.99, the stock trades at about 12.8 times the new guidance midpoint of $5.70. It is up about 27% this year and sits below its 52-week high of $77.06.

Bull case, bear case, what to watch

Bull case

Pricing power keeps converting falling volumes into rising profit, quarter after quarter.
A raised outlook, a growing dividend and a bigger buyback point to management confidence.
About 12.8x earnings with a ~6% yield is inexpensive next to the broader market.

Bear case

Cigarette volume declines of about 4% a year compound, and Marlboro is losing share to discount brands, including Altria's own.
Oral tobacco profit is shrinking, and on! is losing ground in the fastest-growing category.
E-vapor remains on hold, and regulation (menthol, nicotine limits, flavor rules) is a standing risk.

What to watch

Marlboro retail share and the premium-to-discount mix
on! share of the pouch category
Any update on NJOY ACE's return
Q4 results in late January and the 2027 outlook

Data caveats

Consensus figures are from MarketBeat and press coverage; other services may show slightly different estimates.
Price, yield, valuation and year-to-date figures use the Oct 28 close of $72.99, before this report. The stock's reaction on Oct 29 is not reflected.
Prior guidance ($5.61–$5.72) is as reported by MarketBeat and Tobacco Insider.

Disclosure: The author owns a small position in MO (under 1% of his portfolio). Not investment advice. Sources: Altria Q3 2026 earnings release (SEC Form 8-K), Tobacco Insider, MarketBeat (Q3 estimates), MarketBeat (Q2 results), Yahoo Finance (price data). Published Oct 29, 2026.